Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C

Daclatasvir (Daklinza™), a new oral direct-acting antiviral, is an inhibitor of hepatitis C virus NS5A protein and has recently been approved in the United States, Europe and Japan in chronic hepatitis C. It shows potent pangenotypic activity and moderately high genetic barrier to resistance improvi...

Descripción completa

Detalles Bibliográficos
Autores principales: Manolakopoulos, Spilios, Zacharakis, George, Zissis, Miltiadis, Giannakopoulos, Vassilis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923813/
https://www.ncbi.nlm.nih.gov/pubmed/27366028
http://dx.doi.org/10.20524/aog.2016.0041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923813/
https://www.ncbi.nlm.nih.gov/pubmed/27366028
http://dx.doi.org/10.20524/aog.2016.0041

Ejemplares similares